Jade Biosciences, Inc. · Brief

Next report

8 days

Nov 13 · before openest.Q3 FY26

Expected move

No implied move.

8 reportsHistory

1 of 8≥ implied

May 1 '25±5.8%▲+24.80%×4.29

May 14 '25±15.0%▼−1.99%×0.13

Aug 13 '25±18.6%▼−7.64%×0.41

Q3 FY25±13.5%▲+10.54%×0.78

Jan 5 '26±26.0%▼−7.34%×0.28

Q1 FY26±29.2%▲+1.22%×0.04

May 7 '26±24.6%▲+6.56%×0.27

Q2 FY26±18.9%▼−1.05%×0.06

quarterimplied−30%0+30%realized×

Q2 FY26±18.9%▼−1.05%×0.06

May '26±24.6%▲+6.56%×0.27

Q1 FY26±29.2%▲+1.22%×0.04

Jan '26±26.0%▼−7.34%×0.28

Q3 FY25±13.5%▲+10.54%×0.78

Aug '25±18.6%▼−7.64%×0.41

2 older reports

May '25±15.0%▼−1.99%×0.13

May '25±5.8%▲+24.80%×4.29

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Nov 13 report · est.

Bull2 of 4

3disclosed supplier and customer ties in SEC filingsSEC filings

4tracked funds holding JBION-PORT · Aug 31 '26

Bear2 of 4

0.32%of State Street SPDR S and P Biotech ETF assets largest fund weightN-PORT · Jun 30 '26

23managers whose positions together make up four fifths of the reported value13F · Jun 30 '26

AI captions · Sep 28 '26once per report · top 2 per case

JBIO report session

No linked exposure.

Oct 30impliedImplied move: ±30.5% into Nov 13 earnings (Oct 30 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.